Sequence: RGD motif (arginine–glycine–aspartate)
| Experiment Id | EXP002031 |
|---|---|
| Paper | Targeted OUM1/PTPRZ1 silencing and synergetic CDT/enhanced chemical therapy toward uveal melanoma ba |
| Peptide | RGD |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | MOF-PR 0–80 µg/mL (dose-dependent assays) |
| Rna Concentration | co-loaded with MOF (not independently specified) |
| Mixing Ratio | |
| Formulation Format | metal–organic framework nanoparticle (MOF-PR) |
| Formulation Components | Mn@MOF + PEG + RGD peptide + siOUM1 + siPTPRZ1 ± cisplatin + ICG |
| Size Nm | 130.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | OCM1a uveal melanoma cells |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown, proliferation, apoptosis |
| Output Value | Strong knockdown of OUM1 and PTPRZ1; reduced proliferation; increased apoptosis |
| Output Units | |
| Output Notes | qPCR, EdU, live/dead staining, ROS assays confirm functional siRNA activity |
| Toxicity Notes | Good biocompatibility vs controls |
| Curation Notes |